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The pathogenesis of epithelial ovarian cancer remains unclear. From epidemiological studies raised levels of androgens have
been implicated to increase the risk of developing the disease. The purpose of this study was to determine the responses of
normal human ovarian surface epithelium to androgens. We have established primary cultures of human ovarian surface
epithelium from patients undergoing oophorectomy for benign disease. Total RNA was isolated from these cultures and
expression of mRNA encoding for the androgen receptor was demonstrated using reverse transcriptase polymerase chain
reaction. The presence of androgen receptor in sections of normal ovary was also investigated using an antibody against
androgen receptor. The effects of androgens on DNA synthesis and cell death were determined. Eight out of eight (100%)
cultures expressed mRNA encoding the androgen receptor. The presence of androgen receptor in ovarian surface epithelium
of sections of normal ovaries was demonstrated in all sections. Mibolerone, a synthetic androgen, caused a signiﬁcant
stimulation of DNA synthesis in 5 out of 9 (55%) cultures when used at a concentration of 1 nM. Mibolerone also caused a
signiﬁcant decrease in cell death in 2 out of 5 (40%) cultures tested. We have demonstrated that the ovarian surface
epithelium is an androgen responsive tissue and that androgens can cause an increase in proliferation and a decrease in cell
death. These ﬁndings have important implications for the pathophysiology of ovarian carcinogenesis.
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Ovarian cancer remains a signiﬁcant health problem. It is a
disease which is characterised by late presentation and a poor
prognosis with an overall 5 year survival rate of 30%. Approxi-
mately 90% of ovarian cancers arise from the ovarian surface
epithelium (OSE), a single layer of cuboidal cells which surround
the ovary and are in continuity with the peritoneal mesothelium,
with which they share a common embryological origin.
The OSE envelopes the ovary and is therefore in close proxi-
mity to the underlying stromal, granulosa and thecal cells.
These cells are responsible for sex steroid hormone production,
namely oestrogen, progesterone and androgens. The factors
controlling the proliferation of the OSE are not well understood,
but it is highly probable that these high levels of local hormones
play some part. Androgens can be postulated to play an important
role because of their relatively high levels in the ovary (Risch,
1998). Androstenedione, which is produced by the ovary and
the adrenal gland, is a relatively weak androgen but the OSE
has been shown to express the enzyme 17b-hydroxysteroid dehy-
drogenase (Blaustein and Lee, 1979) which can convert
androstenedione to testosterone, a much more potent androgen.
Androstenedione and testosterone are both found in the develop-
ing ovarian follicle, in concentrations exceeding those of
oestrogens (McNatty et al, 1979; Eden et al, 1990). In addition,
plasma concentrations of androgens are higher than those of
oestrogens, even during the late follicular phase of the cycle (Carr,
1993).
From epidemiological studies, an association between androgens
and ovarian cancer has been known for some time. Conditions in
which serum levels of androgens are raised such as polycystic ovar-
ian syndrome have been shown to be associated with ovarian
cancer (Schildkraut et al, 1996), and a nested case control study
also showed that elevated levels of circulating androgens were asso-
ciated with the development of ovarian cancer (Helzlsouer et al,
1995). Use of the combined oral contraceptive has been shown
to be protective against ovarian cancer (Purdie et al, 1995; Vessey
and Painter, 1995) and has also been demonstrated to suppress
ovarian testosterone production (Gaspard et al, 1983). Lastly,
administration of testosterone to guinea pigs has been demon-
strated to induce benign ovarian epithelial tumours (Silva et al,
1997).
Expression of the androgen receptor (AR) has been demon-
strated in ovarian cancers using ligand binding assays (Hamilton
et al, 1981). Further studies have shown AR to be expressed by
as many as 90% of epithelial ovarian cancers (Kuhnel et al,
1987). There appears to be no correlation between AR expression
and histological type of cancer (Chadha et al, 1993), and the
proportion of cells within each tumour expressing the receptor
varies from 10-90% (Chadha et al, 1993).
The presence of androgen receptor mRNA (Lau et al, 1999)
and protein (Chadha et al, 1994) has been reported in OSE cells.
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www.bjcancer.comHowever, dihydrotestosterone failed to stimulate proliferation of
primary cultures of OSE cells (Karlan et al, 1995).
In ovarian cancer cell lines it has been shown that administra-
tion of dihydrotestosterone results in a dose dependant down
regulation of TbR-II mRNA. TbR-II is a receptor for TGFb,
which in turn is a potent inhibitor of epithelial cell proliferation
(Evangelou et al, 2000). Using primary cultures of ovarian
cancers, a dose dependant inhibitory effect of anti-androgens
has been demonstrated (Slotman and Rao, 1989). However the
administration of dihydrotestosterone at a dose of 100 nM did
not lead to an increase in cell number over 10 days (Slotman
and Rao 1989).
Several studies have demonstrated an increase in plasma
levels of androgens in patients with ovarian cancer when
compared with controls (Carlstrom et al, 1985; Jeppson et al,
1986), and also a correlation between plasma levels of andros-
tenedione with tumour stage and volume (Mahlck et al,
1986). Production of androgens is seen to decrease following
chemotherapy (Mahlck et al, 1986). These reports, taken in
conjunction with the data regarding androgen receptor status
of tumours, suggest that ovarian cancers have an autocrine
growth loop being able to both produce and respond to andro-
gens (Mahlck et al, 1986).
Mibolerone is a synthetic androgen (7a,17a-dimethyl 19-nortes-
tosterone) which has several advantages over natural androgens for
in vitro studies. It is not metabolised, unlike dihydrotestosterone,
which can be metabolised in vitro (Carlson and Katzanallenbogen,
1990). It binds exclusively to the androgen receptor (Carlson and
Katzanallenbogen, 1990) and has been shown to have comparable
effects to dihydrotestoterone at doses of 0.1–10 nM (Birrell et al,
1995).
In this study we conﬁrm the presence of androgen receptor in
hOSE and demonstrate that the synthetic androgen mibolerone
can signiﬁcantly induce cell proliferation and inhibit cell death of
primary cultures of normal human OSE.
MATERIALS AND METHODS
Materials
Sections of normal ovary were obtained, and primary cultures were
established from women undergoing oophorectomy for benign
disease, in most cases hysterectomy and oopherectomy for menor-
rhagia. All patients gave written consent and approval was granted
from the local ethics committee.
Primary cultures of human ovarian surface epithelium were
established according to the method of Auersperg (Kruk et al,
1990). Brieﬂy, ovaries were scraped using a cell scraper to release
the ovarian epithelium, which is only tenuously attached to the
underlying stroma. The sheets of epithelium removed were trans-
ported in Hanks’ buffered salt solution (Gibco, Paisley, UK)
before centrifugation. They were then resuspended in medium
comprising 45% (v/v) RPMI (Gibco, Paisley, UK) and 45% (v/v)
Ham’s F-12 (Gibco, Paisley, UK) with 10% (v/v) fetal calf serum
with added penicillin and streptomycin. Once established the
cultures were maintained in this medium in an atmosphere of
5% CO2,a t3 7 8C.
Characterisation of the cultures was achieved by staining ﬁxed
preparations of the cultures with antibodies to a panel of cytoker-
atins, in particular cytokeratins 7, 8, 18 and 19 (Auersperg et al,
1994). Using costaining techniques, with propidium iodide to
stain all nuclei, an estimate of the epithelial content could be
made.
The ovarian cancer cell line MDAH 2774 and the androgen
sensitive prostate cancer cell lin LNCAP were obtained from the
American Tissue Culture Collection (Rockville, MD, USA). The
ovarian cancer cell line 41M was obtained from Dr AP Wilson
(Oncology Research Centre, Derby, UK).
Mibolerone was obtained from Sigma Chemicals (Poole, Dorset,
UK) and reconstituted in phosphate buffered saline.
Immunohistochemistry
Parafﬁn sections of formalin ﬁxated tissue were dewaxed in
xylene and rehydrated in graded ethanol and treated with 0.5%
hydrogen peroxide in methanol for 30 min. Slides were washed
in Tris buffered saline before being treated with 0.1 M citric acid
pH 6.0 for 20 min at 958C. Following antigen retrieval the slides
were blocked with 20% (v/v) rabbit serum (Dako Ltd, Ely,
Cambridgeshire, UK) in phosphate buffered saline (PBS) and
1% (w/v) bovine serum albumin, for 20 min. Sections were incu-
bated at room temperature for 4 h with primary antibody, either
clone AR441 mouse monoclonal antibody against androgen
receptor (Dako) or clone LP34, mouse monoclonal antibody
against pancytokeratin (Dako), both at dilutions of 1 in 50.
Slides were washed before being treated with a biotinylated
rabbit anti mouse secondary antibody for 45 min, again at a 1
in 50 dilution. The slides were then washed and developed with
the streptavidin-biotin/horseradish peroxidase complex kit (Dako)
according to the manufacturer’s instructions. Finally the slides
were dehydrated using graded alcohols before being mounted
with DPX.
To act as negative controls sections were also incubated with
secondary antibody alone before being processed as described
above.
Androgen receptor expression was assessed and scored by two
investigators independently (RJ Edmondson and BR Davies). A
scoring system was applied with each section being scored with a
range of 0–30, calculated as the product of the percentage of cells
stained divided by 10 by the intensity of staining (three point
scale). Any differences of opinion were resolved by averaging the
results.
RT–PCR
Reverse transcriptase polymerase chain reaction (RT–PCR) was
performed on total RNA extracted from primary cultures.
1610
6 cells in monolayer culture were trypsinised and centrifuged.
Total RNA was extracted using the RNeasy (Qiagen, UK) kit
according to the manufacturer’s instructions. Total RNA was quan-
tiﬁed using a spectrophotometer and 1 mg of RNA was used to
construct cDNA using the Superscipt II (Gibco, Paisley, UK) kit,
again according to the manufacturer’s instructions.
For the androgen receptor an exon spanning fragment stretch-
ing from nucleotide position 1653 in exon 1 to position 2845 in
exon 4 (Lubhahn et al, 1989) was ampliﬁed using the sense
primer 5'-TGG ATG GAT AGC TAC TCC GG-3' and the anti-
sense primer 5'-ACT ACA CCT GGC TCA ATG GC-3' (Nitsche
et al, 1996), to give a product of 479 base pairs. For GAP-DH
expression an exon spanning fragment was ampliﬁed using the
sense primer 5'- AAA TGA GCC CCA GCC TTC T-3', and the
antisense primer 5'- AGT CAA CGG ATT TGG TCG TA, to give
a product of 315 base pairs.
A PCR reaction was made containing sense and antisense
primers at a concentration of 200 nM, dNTP mixture at a concen-
tration of 200 mM of each base, 4 units of Taq polymerase and 2 ml
of cDNA. For the androgen receptor PCR the mixture was heated
to 958C for 5 min before being subjected to 36 cycles as follows;
948C for 75 s, 608C for 90 s and 728C for 120 s before a ﬁnal elon-
gation phase at 728C for 7 min. For expression of GAP-DH the
mixture was heated to 958C for 5 min before being subjected to
22 cycles as follows; 948C for 60 s, 548C for 60 s and 728C for
120 s before a ﬁnal elongation phase at 728C for 7 min. In order
to calculate the optimum cycle number for every culture, a PCR
reaction was performed and stopped after every two cycles.
Thirty-six and 22 cycles represent, respectively the linear phase of
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cDNA concentration.
PCR products were visualised using 2% (w/v) agorose gel elec-
trophoresis and ethidium bromide staining. Gels were
photographed on the gel-doc apparatus (Biorad).
A positive control reaction using RNA extracted from the
androgen sensitive prostate cancer cell line LNCAP was also
performed. A negative control used only buffer in the absence of
RNA.
DNA synthesis assays
DNA synthesis was measured using tritiated thymidine incorpora-
tion assay. Cells were plated at a density of 1610
4 cells per well of
a 60-well plate. The cells were plated initially in full serum
medium. After 4 h this medium was replaced with serum free
medium with the addition of bovine serum albumin at a concen-
tration of 250 mgm l
71 for a further 24 h in order to reduce the
number of actively proliferating cells prior to the addition of
growth factors. Varying concentrations of mibolerone were then
added to the cultures. Recombinant EGF (1 ng ml
71) and IGF
(1 ng ml
71) were also added to some cultures for comparison.
Tritiated thymidine (Amersham, Bucks, UK) was added to the
cultures to give a ﬁnal concentration of 3 mCi ml
71 of medium.
After 24 h the cells were lifted from monolayer culture with Tryp-
sin/EDTA and lysed with 10% trichloroacetic acid before being
harvested onto a glass ﬁbre ﬁlter using a cell harvester (Wallac,
Turku, Finland). Radioactivity was measured using a scintillation
counter (Wallac). All assays were performed using six replicates
per treatment group.
The JAM assay
During cell death one of the most consistent intracellular phenom-
ena is the fragmentation of the genomic DNA. This can be
measured using the JAM assay (Matzinger, 1991). Brieﬂy, prolifer-
ating cells in monolayer culture were labelled with tritiated
thymidine at a concentration of 3 mCi ml
71 of medium for 24 h.
The cells were then washed to remove unbound tritiated thymidine
and cultured in the presence of mibolerone in a 96-well plate. After
either 24 or 48 h the cells were lysed and harvested onto a glass
ﬁbre mat before being counted on a scintillation counter. During
the harvesting process fragmented DNA passes through the glass
ﬁbre mat whilst intact DNA is trapped, therefore the amount of
radioactivity present on the mat is inversely proportional to the
amount of cell death occurring during the time of the assay. Cells
exposed to mibolerone were compared to cells in serum free media.
Cells were also exposed to staurosporin (Sigma, UK) (2.5 mM), a
known inducer of apoptosis as a positive control.
The apoptotic index (AI) is given by the difference between the
mean count per minute for the cells with mibolerone and the mean
count for cells in serum free medium divided by the mean for cells
in serum free medium and expressed as a percentage.
Statistics
The Mann–Whitney U-test was used to compare differences in
numbers of androgen receptor positive cells between OSE and
epithelium within inclusion cysts. Effects on DNA synthesis and
cell death were analysed using the unpaired t-test to compare cells
stimulated with mibolerone with cells grown in serum free
medium. P values less than 0.05 were considered signiﬁcant with
P values less than 0.01 considered highly signiﬁcant. The effects
of mibolerone across a series of cultures were compared using
the two way analysis of variance (two-way ANOVA).
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GAP-DH 315 bp
androgen receptor 479bp
Figure 2 Reverse transcriptase PCR of mRNA extracted from eight primary cultures of normal OSE showing expression of mRNA encoding for andro-
gen receptor compared to expression of the constitutive gene GAP-DH.
A
B
Figure 1 Ovarian surface epithelium in monolayer culture. (A) Photomi-
crograph of normal OSE grown in monolayer culture demonstrating typical
appearance of epithelial phenotype. (B) Photomicrograph of methanol-
ﬁxed OSE cells stained with cytokeratin-18 anti-serum to conﬁrm epithelial
phenotype of the cultures.
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Establishing primary cultures of human OSE (hOSE)
During the ﬁrst two passages hOSE cultures were epithelial like in
morphology, growing in cobblestone monolayers (Figure 1A), but
became increasingly elongated as they approached senescence. For
this reason, early passage cells with epithelial morphology were
utilised in subsequent functional studies. Immediately before carry-
ing out experiments the epithelial phenotype was conﬁrmed using
antibodies to cytokeratins (Figure 1B). Cultures utilised for experi-
ments all contained greater than 95% cytokeratin positive epithelial
cells.
Demonstration of the expression of the androgen receptor
in normal OSE
A PCR cDNA product corresponding to the androgen receptor
mRNA was detected in 8 out of 8 (100%) primary cultures of human
OSE (Figure 2). An identical band was produced using RNA from the
androgen sensitive prostate cancer cell line LNCAP, (not shown). The
presence of the constitutively expressed mRNA of GAP-DH was
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Table 1 The effects of two different concentrations of mibolerone (1 and 100 nM) on DNA synthesis of human ovarian epithelial
cells
Menopausal
1n M 100 nM
Culture Age status CPM nil
a CPM mib
b s.e.
c Induction
d CPM nil
a CPM mib
b s.e.
c Induction
d
hOSE 25 46 Pre 123.5 169.5 20.6 1.4 123.5 204.2 23.3 1.7**
hOSE 40 42 Pre 322.3 388.5 26.8 1.2 322.3 242.5 19.1 0.8
hOSE 41 53 Post 120.7 138.5 8.8 1.1 120.7 122.7 5.3 1.0
hOSE 45 45 Pre 16 44.0 18.1 2.8** 16 37.8 21.2 2.4**
hOSE 47 61 Post 158.3 254.3 74.2 1.6* 158.3 99.2 61.2 0.6
hOSE 49 45 Pre 30.5 46.2 15 1.5 30.5 28.9 3.9 1.0
hOSE 60 48 Pre 26.8 48.0 3.0 1.8** 26.8 60.5 20.9 2.3
hOSE 62 50 Post 87.7 118.9 11.8 1.4* 87.7 129.7 34.7 1.5
hOSE 64 45 Pre 379.3 483.2 37.9 1.3* 379.3 319.7 35.3 0.8
aMean count per minute of cells grown in the absence of serum or steroid.
bMean count of cells grown in the presence of mibolerone.
cStandard error of
the mean.
dInduction calculated by CPMmib/CPMnil. *P50.05. **P50.01.
A
C
E F
D
B
Figure 3 Androgen receptor expression in sections of normal human ovary and fallopian tube. (A) Section of normal fallopian tube showing strong
epithelial expression of the androgen receptor. (B) Androgen receptor positive granulosa (G) and stromal (S) cells in a developing follicle within normal
ovary. (C) Androgen receptor positive OSE cells lining a normal ovary. (D) Androgen receptor negative OSE cells from a different patient lining a normal
ovary. (E) Androgen receptor positive epithelium within an inclusion cyst in normal ovary. (F) Cytokeratin positive OSE in normal ovary demonstrating
epithelial phenotype.
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compared using GAP-DH expression as a standard using semi quan-
titative RT–PCR. The ratio of expression of AR to GAP-DH cDNA
product ranged from 0.62 to 1.58 (mean 1.03) indicating that the
level of AR expression varied by a factor of 2.5-fold between the high-
est and lowest expressing cultures. There was no correlation between
level of receptor expression and age or menopausal status of the
patient from whom the OSE was cultured.
Sections of normal ovary taken from six different patients were
examined for the presence of androgen receptor. Immunostaining
for AR was strong in adjacent areas of fallopian tube (score 20
out of 30), (Figure 3A), stromal cells (18 out of 30) (Figure 3B)
and granulosa cells (20 out of 30) (Figure 3B). The immunostain-
ing with antisera to the AR in OSE cells was very heterogeneous,
with some areas of OSE giving intense positive staining (Figure
3C), whilst other areas remained negative (Figure 3D). However,
all normal ovaries contained some AR positive OSE cells (mean
score 8.2+2.0). In all cases the OSE examined were situated imme-
diately overlying stromal tissue.
The epithelium within inclusion cysts also stained heteroge-
neously (Figure 3E), the mean number of AR positive cells was
greater than seen in OSE cells (mean 9.7+2.3) but this failed to
reach the 5% signiﬁcance level when the Mann–Whitney test
was applied.
Serial sections of ovary were stained with anticytokeratin anti-
sera to aid with identiﬁcation of epithelial cells (Figure 3F).
Negative control sections failed to demonstrate any expression of
either androgen receptor or cytokeratin.
The effect of mibolerone on proliferation of normal OSE
cells
The effects of two concentrations of mibolerone on nine primary
cultures of human OSE were studied after 24 h incubation. A
concentration of 100 nM mibolerone signiﬁcantly stimulated
DNA synthesis in 2 out of 9 primary cultures after 24 h by between
1.6- and 2.6-fold, whilst a concentration of 1 nM caused increased
DNA synthesis in 5 out of 9 cultures ranging from 1.3- to 2.8-fold
(Table 1). Comparison of means for all cultures tested demon-
strates a highly signiﬁcant increase in DNA synthesis after
administration of 1 nM mibolerone, P=0.003 (two-way ANOVA),
but no signiﬁcant effect for 100 nM mibolerone, P=0.58 (two-way
ANOVA).
The magnitude of this stimulation was similar to that of other
known growth factors for the OSE, namely EGF (1 ng ml
71)
(2.8-fold induction) and IGF (1 ng ml
71) (2.0-fold induction).
The effects of mibolerone on proliferation of cancer cell
lines
In the ovarian cancer cell lines 41M and MDAH, concentrations of
mibolerone less than 10 nM all slightly induced mean DNA synth-
esis. This reached statistical signiﬁcance at 100 pM mibolerone
(Figure 5), which gave a 1.6-fold (P50.02) increase in DNA synth-
esis when compared with cells in serum free medium.
The effects of mibolerone on cell death in normal OSE cells
Mibolerone, at concentrations of both 100 and 1 nM caused a
signiﬁcant decrease in cell death in 3 of 5 primary cultures of
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10000
8000
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4000
2000
0
mibolerone concentration
41M
MDAH
Figure 5 Effect of adding mibolerone to cultures of the ovarian cancer cell lines 41M and MDAH. Tritiated thymidine was added to the cultures imme-
diately following addition of mibolerone and the cells were harvested 24 h later. The increase in DNA synthesis was signiﬁcantly greater than cells in serum
free medium with a dose of 100 pM in both cultures (P50.02, t-test).
nil EGF IGF Mib Mib serum
100 nM 1n M
C
P
M
600
500
400
300
200
100
0
Figure 4 The effects of mibolerone on cells from a primary culture of
human ovarian surface epithelium (hOSE 45). Tritiated thymidine was
added after the addition of growth factor or 10% serum. Cells were har-
vested 24 h later. The assay was performed with six replicates. ** Denotes
signiﬁcantly increased DNA synthesis than cells in serum free medium
(P50.01 t-test).
Androgens and ovarian surface epithelium
RJ Edmondson et al
883
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(6), 879–885hOSE. Cell death was less when cultures were exposed to 1 than
100 nM mibolerone (Figure 6). As expected staurosporin signiﬁ-
cantly induced apoptosis (AI 72) (Figure 6).
DISCUSSION
Although it has long been recognised that the ovary expresses
androgen receptors (Al-Timimi et al, 1985) this is the ﬁrst time
that the AR has been shown to be functional in human OSE cells.
We have demonstrated that in the majority of cases primary
cultures of hOSE can respond to androgens within 24 h with a
signiﬁcant induction of DNA synthesis and in some cases a protec-
tion from cell death. The use of primary cultures of hOSE allows
these cells to be isolated from ovarian inﬂuences while at the same
time avoiding the adverse cellular changes associated with long-
term culture of these particular cells.
The OSE, therefore, is an androgen responsive tissue that plays
an integral role in ovarian physiology and is subject to physiologi-
cal regulation by the androgen synthesising cells of the ovarian
follicle and systemic circulating androgens. The factors controlling
expression of the AR in human OSE are not known, but appear to
be unrelated to age or menopausal status. Given that AR expression
is heterogeneous even within individual ovaries, it may be related
to the differentiation state of the OSE or controlled by local para-
crine factors.
In the physiological state, proliferation of OSE cells is thought to
occur during the process of ovulation and/or folliculogenesis. High
concentrations of androgens in follicular ﬂuid may play a signiﬁ-
cant role as paracrine factors in the survival and proliferation of
OSE cells. In this context, it is interesting to note that stimulation
of DNA synthesis in mouse OSE in vivo was reported to be maxi-
mal when the OSE was immediately overlying developing follicles
(Davies et al, 1999).
It is well recognised that the ovarian epithelium forms inclusion
cysts and clefts, which are thought to form as part of the ovulatory
repair mechanism. It has been suggested that many ovarian cancers
arise from these inclusion cysts (Fox, 1993). OSE cells in clefts and
cysts also express the AR; and these cells are potentially in closer
proximity to the androgen producing cells of the ovarian cortex.
This may have relevance in the pathogenesis of EOC.
Previous studies examining the effects of dihydrotestosterone on
OSE failed to show any signiﬁcant increase in DNA synthesis
(Karlan et al, 1995). The reasons for this difference are unclear,
although may be related to different sensitivities of the two assays,
cell counting and DNA synthesis, used.
We have shown that androgens can cause a signiﬁcant stimula-
tion of DNA synthesis within 24 h. It is not known whether the
mechanism of stimulation is via induction of cell cycle progression
genes such as cyclin D1, androgen-responsive growth factor genes
eg FGF-8, or down regulation of the TGFb-II receptor as in
EOC cell lines (Evangelou et al, 2000).
Stimulation of the ovarian cancer cell lines with mibolerone
leads to a signiﬁcant increase in proliferation, particularly at the
lower doses used. This ﬁnding is in contradiction to previous
reports which found no increased proliferation in primary cultures
of ovarian cancer (Slotman and Rao, 1989), but is consistent with
our ﬁndings that androgens cause proliferation in OSE, the tissue
of origin of ovarian cancer. Since the identiﬁcation of androgen
receptors in ovarian cancers there have been speculations that this
represents an autocrine growth loop (Mahlck et al, 1986) and a
possible target for anti androgen therapy (Rao et al, 1990).
In conclusion we have shown, for the ﬁrst time, that the tissue
of origin of epithelial ovarian cancer, the OSE, can respond to
androgens. The ﬁnding that the normal OSE is responsive to
androgens is of major importance in that it opens up the possibi-
lity that androgens have a role in ovarian carcinogenesis rather
than just represent an upregulated activity within developed malig-
nancy. The physiological mechanisms of androgen action in OSE
cells deserve further investigations.
ACKNOWLEDGEMENTS
RJ Edmondson was supported by the Northern Cancer Care and
Research Society and Gateshead NHS Healthcare Trust.
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
a
p
o
p
t
o
t
i
c
 
i
n
d
e
x
100
50
0
–50
–100
–150
–200
hOSE 57
hOSE 60
hOSE 62
hOSE 72
hOSE 85
1n M 100 nM staurosporin
mibolerone mibolerone
Figure 6 The effect of mibolerone on cell death of OSE cells for ﬁve cultures of hOSE exposed to 100 nM and 1 nM mibolerone. The effects of staur-
osporin, an inducer of apoptosis are shown for comparison. * Denotes signiﬁcantly more/less cell death than cells in serum free medium P50.05, ** De-
notes signiﬁcantly more/less cell death than cells in serum free medium P50.01.
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